Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 68.6 GBX 2.39% Market Closed
Market Cap: £286.7m

Net Margin

11.3%
Current
Declining
by 15.4%
vs 3-y average of 26.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.3%
=
Net Income
£5.2m
/
Revenue
£46m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.3%
=
Net Income
GBX5.2m
/
Revenue
£46m

Peer Comparison

Country Company Market Cap Net
Margin
UK
Niox Group PLC
LSE:NIOX
279.9m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Higher than 97% of companies in United Kingdom
Percentile
97th
Based on 3 670 companies
97th percentile
11.3%
Low
-188 120% — 0%
Typical Range
0% — 0.1%
High
0.1% — 10 443.9%
Distribution Statistics
United Kingdom
Min -188 120%
30th Percentile 0%
Median 0%
70th Percentile 0.1%
Max 10 443.9%

Niox Group PLC
Glance View

Market Cap
286.7m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.94 GBX
Overvaluation 29%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11.3%
=
Net Income
£5.2m
/
Revenue
£46m
What is Niox Group PLC's current Net Margin?

The current Net Margin for Niox Group PLC is 11.3%, which is below its 3-year median of 26.7%.

How has Net Margin changed over time?

Over the last 3 years, Niox Group PLC’s Net Margin has decreased from 47.6% to 11.3%. During this period, it reached a low of 8.9% on Dec 31, 2024 and a high of 51.4% on Dec 31, 2022.

Back to Top